NEW YORK, NY–(Marketwired – Mar 27, 2015) – The following statement is being issued by Levi & Korsinsky, LLP:
TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED COMMON SHARES OF ACCELERATE DIAGNOSTICS, INC. (NASDAQ: AXDX) BETWEEN MARCH 7, 2014 AND FEBRUARY 17, 2015.
YOU ARE HEREBY NOTIFIED that a securities class action lawsuit has been commenced in the United States District Court for the District of Arizona. If you purchased or otherwise acquired Accelerate Diagnostics, Inc. (“Accelerate”) securities between March 7, 2014, and February 17, 2015, YOUR RIGHTS MAY BE AFFECTED BY THIS ACTION. To get more information, GO TO:
Or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that the Company misrepresented and/or failed to disclose that its main product, the ID/AST system — formerly known as the BACcel system — requires a positive blood culture to diagnost pathogens in a blood sample.
On February 18, 2015, Seeking Alpha published an article asserting that though Accelerate Diagnostics had claimed it had developed a technique for diagnosing pathogens in a blood sample without the need of a blood culture, this test did in fact require a blood culture, significantly reducing its value. Upon this news shares of Accelerate Diagnostics fell more than 18% on February 20, 2015.
If you suffered a loss in Accelerate Diagnostics you have until May 18, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.